Genscript Biotech Corporation (HKG:1548)
11.79
+0.52 (4.61%)
Jun 18, 2026, 4:08 PM HKT
Genscript Biotech Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Genscript Biotech stock has a consensus rating of "Strong Buy" and an average price target of $17.68. The average 1-year stock price forecast is 49.96% higher than the current stock price, while the lowest is $15.50 (+31.47%) and the highest is $21.02 (+78.29%).
Price Target: $17.68 (+49.96%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 14, 2026.
Analyst Ratings
The average analyst rating for Genscript Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 6 | 6 | 6 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Guotai Haitong No rating | Guotai Haitong | Buy Maintains $25.57 | Buy | Maintains | $25.57 | +116.88% | May 14, 2026 |
| Jefferies | Jefferies | Buy Maintains $15.50 | Buy | Maintains | $15.50 | +31.47% | Apr 3, 2026 |
Unknown Analyst J.P. Morgan No rating | J.P. Morgan | Buy Maintains $24.00 → $20.00 | Buy | Maintains | $24.00 → $20.00 | +69.64% | Mar 19, 2026 |
Unknown Analyst CICC No rating | CICC | Buy Maintains $17.90 | Buy | Maintains | $17.90 | +51.82% | Mar 19, 2026 |
Unknown Analyst Huatai Securities No rating | Huatai Securities | Buy Maintains $16.26 | Buy | Maintains | $16.26 | +37.91% | Mar 18, 2026 |
Financial Forecast
Revenue This Year
815.78M
from 959.53M
Decreased by -14.98%
Revenue Next Year
931.12M
from 815.78M
Increased by 14.14%
EPS This Year
0.03
from 0.11
Decreased by -67.17%
EPS Next Year
0.06
from 0.03
Increased by 79.71%
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 902.5M | ||
| Avg | 815.8M | ||
| Low | 785.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -5.9% | ||
| Avg | -15.0% | ||
| Low | -18.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.05 | ||
| Avg | 0.03 | ||
| Low | 0.02 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -53.4% | ||
| Avg | -67.2% | ||
| Low | -81.0% |